Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TD1414 2% Cream in Impetigo and SITL
NCT00626795Phase 2Completed
- Sponsor
- LEO Pharma
- Start
- Feb 2008
- Primary completion
- Mar 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 2, randomised, single-blind trial of zibrofusidic acid in impetigo and post-traumatic wound infection (3 arms), sponsored by LEO Pharma. Primary endpoint: Participants With Clinical Cure According to Investigator's Assessment at Day 8. Started Feb 2008; status: completed.
02
Drugs
zibrofusidic acid
03
Conditions
impetigopost-traumatic wound infection
Beyond the preview
Go deeper on NCT00626795.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00626795.